Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory (2021 - 2025)

Historic Inventory for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $122.8 million.

  • Apellis Pharmaceuticals' Inventory rose 145.47% to $122.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.8 million, marking a year-over-year increase of 145.47%. This contributed to the annual value of $81.4 million for FY2024, which is 4438.17% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Inventory is $122.8 million, which was up 145.47% from $121.0 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Inventory peaked at $161.3 million during Q1 2024, and registered a low of $1.7 million during Q3 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Inventory had a median value of $85.6 million in 2022 and averaged $84.7 million.
  • Its Inventory has fluctuated over the past 5 years, first soared by 346308.88% in 2022, then plummeted by 4886.75% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Inventory stood at $16.3 million in 2021, then skyrocketed by 426.3% to $85.7 million in 2022, then surged by 70.76% to $146.4 million in 2023, then tumbled by 44.38% to $81.4 million in 2024, then skyrocketed by 50.88% to $122.8 million in 2025.
  • Its last three reported values are $122.8 million in Q3 2025, $121.0 million for Q2 2025, and $82.5 million during Q1 2025.